InsiderPulse| Date | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|
| 2026-04-30 | Lu Peng | Chief Medical Officer | Sale | 15.0K | $30.24 | $454K | 66.1K | View ↗ | |
| 2026-04-30 | Schikan Johannes Gerardus Christiaan Petrus | Director | Sale | 29.1K | $30.32 | $881K | 355.2K | View ↗ | |
| 2026-04-30 | Lesage Anne | Chief Early Development | Sale | 40.9K | $30.26 | $1.24M | 56.5K | View ↗ | |
| 2026-04-29 | Lu Peng | Chief Medical Officer | Sale | 3,733 | $30.06 | $112K | 62.4K | View ↗ | |
| 2026-04-29 | Schikan Johannes Gerardus Christiaan Petrus | Director | Sale | 3,830 | $30.07 | $115K | 384.2K | View ↗ |
No financial data available for PHVS.
Company may not file with SEC or CIK is unresolved.
For Pharvaris Investors, the Director's Sale Matters Less Than What's Coming Next
KalVista Scores $1.9 Billion Takeover Deal; Why A Key Rival Jumped Too
Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference
Pharvaris N.V. (PHVS) Presents at CIIC Spring 2026 Conference - Slideshow